View Author
scopus: 7004238144

Voorbij, H.A.M.

(Hieronymus Voorbij)


preeclampsia early-onset preeclampsia tlr 4 hellp syndrome women activity early-onset plasma level allelic variants control history study syndrome hellp variant pregnancy nod 2 serum paraoxonase-i activity fibrinogen plasma levels serum delivery paraoxonase-i allelic patient receptor university response sicam paraoxonase tertile simvastatin value control subjects disease interval hypertension hdl cholesterol cholesterol bezafibrate center subject association analysis protein type 2 treatment diabetes position factor paraoxonase activity odds ratios netherland regression analysis marker table type 2 diabetes utrecht il -6 toll-like body-mass index ratio center utrecht biomarker group von willebrand factor phenyl acetate arylesterase immunity system hypertensive disorders placebo-controlled crossover study paraoxonase-i activity pro-inflammatory polymorphism effect addition genotype inclusion




2 Most Recent Publications

Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus (Article)
Dullaart, R.P.F. Vries, R. de Voorbij, H.A.M. Sluiter, W.J. Tol, A. van
2009-03-01
Maternal TLR4 and NOD2 gene variants, pro-inflammatory phenotype and susceptibility to early-onset preeclampsia and HELLP syndrome (Article)
Rijn, B.B. van Franx, A. Steegers-Theunissen, R.P.M. Groot, C.J.M. de Bertina, R.M. Pasterkamp, G. Voorbij, H.A.M. Bruinse, H.W. Roest, M.
2008-04-02